Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Beth Bash

Nurse Practitioner Butler, PA Nurse Practitioner

NPI 1225079973 CMS profile 11033456

206 S Duffy Rd, Butler, PA 16001

Open in the dashboard

General payments

$6,767

413 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Beth Bash of Butler, PA is reported in the CMS Open Payments database as having received $6,767 across 413 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,444 84
2024 General $1,736 93
2023 General $1,219 75
2022 General $1,173 81
2021 General $1,195 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Beth Bash
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Beth Bash were reported at $1,444. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Beth Bash Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,195 $135 $40–$426 $132
2022 $1,173 $152 $48–$470 $149
2023 $1,219 $166 $54–$529 $160
2024 $1,736 $173 $55–$556 $164
2025 $1,444 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. GlaxoSmithKline, LLC. $1,236 77 payments
  2. Novo Nordisk Inc $857 53 payments
  3. AbbVie, Inc. $846 53 payments
  4. Lilly USA, LLC $646 37 payments
  5. AstraZeneca Pharmaceuticals LP $521 32 payments
  6. Pfizer Inc. $432 24 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $225 14 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $194 12 payments
  9. Amgen Inc. $192 13 payments
  10. Teva Pharmaceuticals USA, Inc. $170 11 payments
  11. Other $1,446 87 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $6,712 409 payments
  2. Long term medical supply or device loan $30 1 payment
  3. Education $25 3 payments
Products named General payments · program years 2021–2025
  1. TRELEGY ELLIPTA $1,194 74 payments
  2. UBRELVY $681 41 payments
  3. Ozempic $577 36 payments
  4. RYBELSUS $499 32 payments
  5. QULIPTA $465 25 payments
  6. JARDIANCE $340 19 payments
  7. XIFAXAN $253 16 payments
  8. FARXIGA $242 13 payments
  9. PAXLOVID $233 13 payments
  10. MOUNJARO $220 11 payments
  11. Other $4,159 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 121 drugs

Part D claims

5,616

Median for Nurse Practitioner: 389

Drug cost

$439,876

Median for Nurse Practitioner: $21,885

Branded share of claims

22.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 101 $83,986
Trulicity Dulaglutide Brand 45 $56,109
Januvia Sitagliptin Phosphate Brand 42 $48,988
Mounjaro Tirzepatide Brand 26 $25,766
Eliquis Apixaban Brand 34 $19,708
Ozempic Semaglutide Brand 16 $19,457
Breo Ellipta Fluticasone/Vilanterol Brand 33 $17,992
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 22 $15,814
Ubrelvy Ubrogepant Brand 12 $13,627
Tradjenta Linagliptin Brand 18 $13,459

The 10 drugs with the highest cost, of 121 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$38,376

Of which drugs: $9,165

Medicare patients

118

Average age 71

Services billed

645

83 women, 35 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 59%
Arthritis 53%
Diabetes 21%
Depression 20%
Ischemic heart disease 19%
Cancer 19%
COPD 17%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 22 22 $6,134
Vaccine for influenza for injection into muscle 90662 Office 33 33 $2,700

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $432
$432 22 —
UBRELVY
  • AbbVie, Inc. $163
$163 12 —
QULIPTA
  • AbbVie, Inc. $145
$145 — —
PAXLOVID
  • PFIZER INC. $125
$125 — —
JARDIANCE
  • Lilly USA, LLC $86
  • Boehringer Ingelheim Pharmaceuticals, Inc. $13
$100 101 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

413 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record